このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Zhejiang Hisun Pharmaceutical 将来の成長

Future 基準チェック /36

Zhejiang Hisun Pharmaceutical利益と収益がそれぞれ年間60.8%と6.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に7% 60.8%なると予測されています。

主要情報

61.1%

収益成長率

47.9%

EPS成長率

Pharmaceuticals 収益成長	18.4%
収益成長率	3.3%
将来の株主資本利益率	5.5%
アナリストカバレッジ	Low
最終更新日	29 May 2024

今後の成長に関する最新情報

Recent updates

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Apr 30

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Mar 29

業績と収益の成長予測

SHSE:600267 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	10,945	513	N/A	N/A	1
12/31/2025	10,684	753	N/A	N/A	1
12/31/2024	10,214	463	N/A	N/A	1
3/31/2024	10,036	-77	1,390	1,513	N/A
12/31/2023	10,373	-93	1,263	1,503	N/A
9/30/2023	11,994	615	1,539	1,909	N/A
6/30/2023	12,360	589	1,339	1,759	N/A
3/31/2023	12,123	586	1,607	2,084	N/A
12/31/2022	12,037	489	1,535	2,066	N/A
9/30/2022	11,773	319	1,507	2,163	N/A
6/30/2022	11,869	526	1,792	2,456	N/A
3/31/2022	12,046	496	1,131	1,793	N/A
12/31/2021	12,136	487	1,114	1,737	N/A
9/30/2021	12,308	574	889	1,363	N/A
6/30/2021	12,040	457	659	1,184	N/A
3/31/2021	11,923	614	663	1,296	N/A
12/31/2020	11,354	417	898	1,590	N/A
9/30/2020	10,914	-819	687	1,362	N/A
6/30/2020	10,724	281	104	1,019	N/A
3/31/2020	10,774	-10	234	1,124	N/A
12/31/2019	11,072	93	-378	698	N/A
9/30/2019	10,694	755	-691	1,098	N/A
6/30/2019	10,522	-455	-335	1,424	N/A
3/31/2019	10,163	-472	-612	1,259	N/A
12/31/2018	10,187	-492	-303	1,446	N/A
9/30/2018	10,200	16	390	1,672	N/A
6/30/2018	10,398	15	501	1,608	N/A
3/31/2018	10,655	18	191	1,554	N/A
12/31/2017	10,572	14	N/A	1,353	N/A
9/30/2017	10,574	-120	N/A	963	N/A
6/30/2017	10,509	-101	N/A	835	N/A
3/31/2017	10,090	-94	N/A	840	N/A
12/31/2016	9,733	-94	N/A	776	N/A
9/30/2016	9,396	40	N/A	594	N/A
6/30/2016	8,986	-3	N/A	413	N/A
3/31/2016	8,793	15	N/A	593	N/A
12/31/2015	8,767	14	N/A	736	N/A
9/30/2015	9,382	85	N/A	637	N/A
6/30/2015	9,835	175	N/A	775	N/A
3/31/2015	10,145	237	N/A	697	N/A
12/31/2014	10,097	308	N/A	571	N/A
9/30/2014	9,645	314	N/A	963	N/A
6/30/2014	9,104	311	N/A	461	N/A
3/31/2014	8,895	303	N/A	630	N/A
12/31/2013	8,604	302	N/A	527	N/A
9/30/2013	7,785	268	N/A	104	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 600267は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.9% ) よりも高い成長率であると考えられます。

収益対市場: 600267今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 600267今後 3 年以内に収益を上げることが予想されます。

収益対市場: 600267の収益 ( 6.7% ) CN市場 ( 13.9% ) よりも低い成長が予測されています。

高い収益成長: 600267の収益 ( 6.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 600267の自己資本利益率は、3年後には低くなると予測されています ( 7 %)。

Zhejiang Hisun Pharmaceutical 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target decreased by 13% to CN¥8.30

Recent updates

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 20, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Full year 2023 earnings released: CN¥0.08 loss per share (vs CN¥0.42 profit in FY 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Investor sentiment deteriorates as stock falls 17%

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Price target decreased by 13% to CN¥8.30

New minor risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.01 in 3Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.43 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.19 in 3Q 2021)

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces an Equity Buyback for CNY 195 million worth of its shares.

Taizhou Jiaojiang State Owned Asset Operation Group Co Ltd agreed to acquire 4% stakes in Zhejiang Hisun Animal Health-care Products Co., Ltd. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 100 million.

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.13 in 2Q 2021)

Shanghai Yuanxun Enterprise Management Center and Hong Kong Summit Nutrition Limited agreed to acquire 34.72% interest of Zhejiang Hisun Sulikang Biotechnology Co., Ltd from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for RMB 17.4 million.

Investor sentiment improved over the past week

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.43 (vs CN¥0.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.074 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.096 in FY 2019)

New 90-day low: CN¥15.49

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: CN¥18.41

CHIPSCREEN and HISUN Reach A Strategic Cooperation

New 90-day low: CN¥15.63

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) signed letter of intent to acquire the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse Capital Management, Ltd for CNY 4.4 billion.

Earnings released

New 90-day high - CN¥18.90

Zhejiang Hisun Pharmaceutical Co., Ltd. announced a financing transaction

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘